T. Rowe Price Associates
HUMA icon

T. Rowe Price Associates’s Humacyte HUMA Stock Holding History

T. Rowe Price Associates’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-112,172
Closed -$69K – 3287
2026
Q1 		$69K Buy
112,172
+36,155
+48% +$37.6K ﹤0.01% 3045
2025
Q4 		$73K Buy
76,017
+13,175
+21% +$18.7K ﹤0.01% 2990
2025
Q3 		$110K Hold
62,842
– – ﹤0.01% 2905
2025
Q2 		$132K Buy
62,842
+25,252
+67% +$48.5K ﹤0.01% 2837
2025
Q1 		$65K Buy
37,590
+3,720
+11% +$14K ﹤0.01% 2895
2024
Q4 		$172K Buy
33,870
+5,801
+21% +$28.7K ﹤0.01% 2740
2024
Q3 		$153K Hold
28,069
– – ﹤0.01% 2740
2024
Q2 		$135K Buy
28,069
+12,216
+77% +$63.6K ﹤0.01% 2694
2024
Q1 		$50K Buy
15,853
+405
+3% +$1.36K ﹤0.01% 2873
2023
Q4 		$44K Buy
15,448
+1,512
+11% +$3.88K ﹤0.01% 2827
2023
Q3 		$41K Buy
13,936
+1,932
+16% +$6.39K ﹤0.01% 2798
2023
Q2 		$35K Hold
12,004
– – ﹤0.01% 2840
2023
Q1 		$38K Buy
+12,004
New +$34.1K ﹤0.01% 2816

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's HUMA Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 112,172 shares — an estimated $69K sold.

T. Rowe Price Associates first reported a position in HUMA in Q1 2023 and held it in 13 quarters. The position peaked at $172K in Q4 2024. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • T. Rowe Price Associates reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 112,172 Humacyte shares in Q2 2026, an estimated $69K.
  • T. Rowe Price Associates first reported a position in Humacyte in Q1 2023 and held it in 13 quarters.
  • T. Rowe Price Associates's Humacyte position peaked at $172K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.